Clinical trial
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"
NCT02655315 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"
- Lead sponsor
- University Hospital, Lille
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 9, 2016
- Completion date
- September 22, 2020
- Enrollment
- 372 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.